Previous studies from our laboratory, demonstrating that suppression of serum FSH by RU486 requires a high estrogen (E) background, suggested that E-inducible progesterone receptors play a role in the regulation of FSH secretion. We demonstrated further that the type II antiprogestin RU486 and the type I antiprogestin ZK98299 both suppressed the elevated serum FSH and FSH␤ messenger RNA levels similarly on the evening of proestrus, but had divergent effects on the morning of estrus, when only RU486, but not ZK98299, lowered the elevated serum FSH level (secondary FSH surge). In the present work we used primary anterior pituitary cell culture to examine whether RU486 caused direct, E-dependent suppression of basal and recombinant human activin A (activin)-induced FSH secretion in the gonadotrope and to compare this direct effect, if any, with that of ZK98299. Primary cell cultures were prepared from anterior pituitaries collected from cycling female rats either on metestrous or proestrous morning and cultured in DMEM, supplemented with charcoal-stripped serum without or with 10 nM estradiol (E 2 ) for 96 h; exposure to test agents occurred during the last 48 h of culture. FSH released into the medium and intracellular FSH content were determined by RIA. In cells from the anterior pituitary of metestrous rats cultured in E 2 -free medium, neither antiprogestin (10 nM) affected FSH release; in contrast, when cells were cultured in medium to which E 2 had been added, both antiprogestins caused profound suppression of both basal and activin (10 ng/ml)-stimulated FSH release. In cell cultures from proestrous rats, both antiprogestins caused a slight, but significant, suppression of basal FSH release even in the absence of added E 2 ; activin-stimulated FSH release, however, was not affected. Upon exposure of the cells from proestrous rats to E 2 , the antiprogestins potently suppressed both basal and activin-stimulated FSH secretion. Because the foregoing incubations were performed in culture medium devoid of progesterone (P 4 ), the actions of the antiprogestins on FSH secretion were independent of the natural ligand. Addition of P 4 (10 nM) to the cell cultures stimulated basal and activininduced FSH release more in the presence than in the absence of E 2 . The FSH response to P 4 was completely blocked by both antiprogestins in both the absence and presence of E 2 . Finally, both RU486 and ZK98299 blocked the stimulatory effect of corticosterone (1 M) on FSH secretion. The observed effects of P 4 and antiprogestins were specific for FSH secretion; LH secretion was not similarly suppressed by either antiprogestin, but was, in fact, stimulated by ZK98299 in E 2 -treated cells. We conclude that 1) E 2 -inducible progesterone receptors interact with activin-mediated signal transduction to regulate FSH secretion, and 2) unlike on the morning of estrus in vivo, RU486 and ZK98299 affect FSH secretion similarly in the gonadotrope in vitro. (Endocrinology 139: [2223][2224][2225][2226][2227][2228] 1998) T HE SECRETION of FSH is controlled, in addition to GnRH and gonadal steroids, by the specific regulatory proteins inhibin, activin, and follistatin, isolated originally from the gonads (1), but shown subsequently to be widely distributed in various tissues, including the pituitary (2, 3). Activin, in particular, has been identified as a key physiological regulator of FSH secretion by virtue of its ability to activate transcription of the FSH␤ gene (4, 5) and, together with follistatin, mediate the effects of pulsatile GnRH administration (6). An additional level of regulation was suggested by previous in vivo studies from our laboratory, which demonstrated an ability of the antiprogestin/antiglucocorticoid RU486 to selectively lower serum FSH (7) in an estrous cycle stage-and estrogen (E)-dependent manner (8). These data suggested that activation of progesterone receptors (PR) is a key component of the specific regulatory mechanism that governs the synthesis and release of FSH. More recently, we compared the effects of RU486 (a type II P antagonist) on FSH secretion in vivo with those of the type I antiprogestin ZK98299; the results indicated that the two antiprogestins, which block PR through different molecular mechanisms (9), have differential effects on serum FSH on the morning of estrus (10). The objective of the present work was to explore in primary pituitary cell culture whether the antiprogestins RU486 and ZK98299 can suppress FSH secretion directly at the level of the gonadotrope, and whether the two antiprogestins can affect FSH secretion differentially in this in vitro system. We investigated the drugs' effects on FSH secretion in the absence and presence of E 2 , under both basal conditions and during stimulation with activin and glucocorticoids, to gain insight into a possible interaction between PR-and activin receptor-mediated signaling in the gonadotrope. The results demonstrate equal, direct, estradiol (E 2 )-dependent suppression of basal and activin-stimulated FSH secretion by both antiprogestins and suggest that under certain physiological conditions, E-inducible PR interact with activin-mediated signaling to stimulate the synthesis and release of FSH.
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GnRH and gonadal steroids, by the specific regulatory proteins inhibin, activin, and follistatin, isolated originally from the gonads (1), but shown subsequently to be widely distributed in various tissues, including the pituitary (2, 3) . Activin, in particular, has been identified as a key physiological regulator of FSH secretion by virtue of its ability to activate transcription of the FSH␤ gene (4, 5) and, together with follistatin, mediate the effects of pulsatile GnRH administration (6) . An additional level of regulation was suggested by previous in vivo studies from our laboratory, which demonstrated an ability of the antiprogestin/antiglucocorticoid RU486 to selectively lower serum FSH (7) in an estrous cycle stage-and estrogen (E)-dependent manner (8) . These data suggested that activation of progesterone receptors (PR) is a key component of the specific regulatory mechanism that governs the synthesis and release of FSH. More recently, we compared the effects of RU486 (a type II P antagonist) on FSH secretion in vivo with those of the type I antiprogestin ZK98299; the results indicated that the two antiprogestins, which block PR through different molecular mechanisms (9) , have differential effects on serum FSH on the morning of estrus (10) . The objective of the present work was to explore in primary pituitary cell culture whether the antiprogestins RU486 and ZK98299 can suppress FSH secretion directly at the level of the gonadotrope, and whether the two antiprogestins can affect FSH secretion differentially in this in vitro system. We investigated the drugs' effects on FSH secretion in the absence and presence of E 2 , under both basal conditions and during stimulation with activin and glucocorticoids, to gain insight into a possible interaction between PR-and activin receptor-mediated signaling in the gonadotrope. The results demonstrate equal, direct, estradiol (E 2 )-dependent suppression of basal and activin-stimulated FSH secretion by both antiprogestins and suggest that under certain physiological conditions, E-inducible PR interact with activin-mediated signaling to stimulate the synthesis and release of FSH.
Materials and Methods Reagents
RU486 (Roussel-UCLAF, Romainville, France), ZK98299 (Schering, Berlin, Germany), E 2 , progesterone (P 4 ), and corticosterone (B; Sigma Chemical Co., St. Louis, MO) were dissolved in absolute ethanol at 1000 times the desired final concentration; the corresponding concentration of ethanol (0.1%) was used as the vehicle. Recombinant human activin A (activin), provided by Dr. Teresa Woodruff, Northwestern University (Evanston, IL), for the initial experiments, and by the National Hormone and Pituitary Program for subsequent ones, was diluted with 0.05 m Tris-HCl (pH 7.4)-0.15 m NaCl from a 0.73 g/ml stock. Media, sera, and all other reagents for cell culture were obtained from Life Technologies (Grand Island, NY).
Animals
Female Sprague-Dawley rats (55-60 days old) were obtained from Charles River (Portage, MI). Animals were housed under a 14-h light, 10-h dark schedule, with lights on at 0500 h, and were provided with standard rat chow and tap water ad libitum. Estrous cycles were monitored by daily vaginal cytology; only rats that exhibited at least two consecutive 4-day estrous cycles were used. Protocols were approved by the animal care and use committee of Northwestern University.
Cell dissociation and culture
Anterior pituitaries were collected from 6 -14 rats at 0900 -1000 h on the specified day of the estrous cycle (usually metestrus) and dissociated enzymatically as previously described (11) . The final pellet was suspended in DMEM containing 10% charcoal-stripped FBS and 10 nm E 2 as indicated. Cells were plated in 24-well culture plates at a density of 3-5 ϫ 10 5 cells/2-cm 2 well and were incubated in a humidified atmosphere of 94% air-6% CO 2 at 37 C for 48 h. Media were collected, fresh media containing the test agents were then added, and incubation was continued for an additional 48 h. Incubation with each test agent was performed in quadruplicate, and each experiment was repeated at least once for confirmation.
FSH and LH release and cell content
Culture media were sampled for FSH and LH release at 48 and 96 h. At the end of the incubation (96 h), cell monolayers were lysed in 1 ml Dulbecco's PBS containing 0.3% BSA and 1% each of Triton X-100 and sodium deoxycholate for determination of intracellular hormone content. All media and lysates were stored at Ϫ20 C until RIA.
Hormone assays
Gonadotropins released into the culture media and their content in the cell lysates were determined by double antibody RIA (7) with reagents supplied by the National Hormone and Pituitary Program.
Statistical analysis
All data presented are the mean Ϯ se of quadruplicate incubations from a single representative experiment. Each experiment was repeated once or twice to ensure reproducibility of the results. The significance of differences between the vehicle-and E 2 -treated cells was assessed by t test. Significant differences among multiple treatment groups were evaluated by multifactor ANOVA (Crisp Program, Crunch Software Corporation, San Francisco, CA). Post-hoc comparisons of the effects of test agents were performed using the Newman-Keuls test. P Ͻ 0.05 was considered significant.
Results

E 2 -dependent suppression of basal FSH secretion by RU486 and ZK98299
Preliminary experiments testing the requirement for E 2 in the culture medium for suppression of FSH secretion by RU486 yielded inconsistent results; these experiments were performed with anterior pituitary cells from rats at random stages of the estrous cycle. Based on this finding and on previous reports demonstrating the importance of the estrous cycle stage in determining the in vitro hormone secretory response to secretagogues (12, 13), we used primary cell cultures prepared from anterior pituitaries collected on metestrous morning when the ambient estrogen background is low. In Exp 1, we examined the effects of the antiprogestins RU486 and ZK98299 (10 nm), added to the primary pituitary cell cultures during the second half of a 96-h incubation, on FSH release into the culture medium (Fig. 1A) and on the intracellular content of FSH (Fig. 1B) upon exposure for various times to 10 nm E 2 . In the absence of E 2 throughout the 96-h incubation, neither antiprogestin (10 nm) had a significant effect on FSH release. Addition of E 2 to the medium during either the first or the second half of the incubation (i.e. before or during the exposure to the antiprogestins) or throughout the entire 96-h incubation did not significantly affect basal FSH release, but enabled the antiprogestins to cause marked suppression of FSH release. The effects of E 2 and antiprogestins on intracellular FSH content were qualitatively similar, but of a lesser magnitude. Because the order and duration of exposure to E 2 had no influence on antiprogestin-induced suppression of basal FSH secretion, a protocol in which E 2 was added throughout the 96-h culture was adopted in all subsequent experiments.
FIG. 1. Effects of treatment with 10 nM RU486 (RU) or ZK98299 (ZK)
on FSH release during 48 -96 h (A) and intracellular FSH content at 96 h (B) in anterior pituitary cell cultures exposed to vehicle or 10 nM E 2 for 48 or 96 h. Pituitaries were collected on the morning of metestrus. Each bar is the mean, and the error bar is the SEM of four observations. In the presence of E 2 , during the first or second 48-h incubation or both, the effects of the antiprogestins on FSH release were highly significant (P Ͻ 0.0001).
E 2 -dependent suppression of basal and activin-stimulated FSH secretion by RU486 and ZK98299: influence of estrous cycle stage
In Exp 2, we tested the effects of RU486 and ZK98299 on FSH release and cell content in the absence and presence of activin (10 ng/ml) in cultured cells from either metestrous or proestrous rats. As in Exp 1, in cells from metestrous rats cultured in steroid-depleted medium ( Fig. 2A, left set of bars) , the antiprogestins had no effect on basal FSH release. Addition of activin caused a robust increase in FSH release, which was also unaffected by the concurrent addition of the antiprogestins. In contrast, when cells from metestrous rats were cultured in medium supplemented with E 2 ( Fig. 2A,  right) , both antiprogestins elicited marked suppression of basal and activin-stimulated FSH release; E 2 enhanced the effects of both activin alone and the antiprogestins on activininduced FSH release. During the first 48 h of incubation without test agents, addition of E 2 to the cell cultures caused a small, but highly significant (P Ͻ 0.0001), increase in FSH released from 21.4 Ϯ 0.53 to 25.1 Ϯ 0.32 ng/ml (data not shown). In cells prepared from pituitaries collected on proestrous morning, i.e. cells derived from a high ambient estrogen environment, the antiprogestins suppressed basal FSH release even in the absence of added E 2 (Fig. 2C, left) . It should be noted, however, that the antiprogestins suppressed only basal, but not activin-stimulated, FSH release in these cultures. Addition of E 2 to the medium in which cells from proestrous rats were cultured enhanced the FSH response to both activin (stimulation) and the antiprogestins (suppression; Fig. 2C, right) . In contrast to cultured cells from metestrous rats, basal release of FSH was unaffected by addition of E 2 to the culture medium during the first 48-h incubation (46.4 Ϯ 1.2 vs.. 47.6 Ϯ 1.2 ng/ml FSH released in the absence and presence of 10 nm E 2 , respectively; data not shown). In cell cultures from both metestrous and proestrous rats, the effects of activin and the antiprogestins on intracellular FSH content were qualitatively similar to those on medium FSH, although of a lesser magnitude (Fig. 2, B and  D) . The in vitro effects of activin and the antiprogestins were concentration dependent (data not shown); the 10 ng/ml activin and 10 nm antiprogestins used in the above studies represent submaximal stimulatory and inhibitory concentrations of the drugs. The in vitro potency of ZK98299 was slightly, but significantly (P Ͻ 0.01), greater than that of RU486 in this and several other experiments, including one in which cells had been prepared from pituitaries collected on estrous morning.
Agonist/antagonist relationship between P 4 and antiprogestins
To investigate the possibility that RU486 and ZK98299 affected FSH secretion in cultured anterior pituitary cells through an agonist-like action, as has been reported in other in vitro systems (14, 15) , in Exp 3, we compared the effects of and proestrous (C and D) rats exposed to vehicle or 10 nM E 2 throughout the 96-h incubation. Each bar is the mean, and the error bar the SEM of four observations. In cultured cells from metestrous rats, addition of E 2 increased the effect of activin (P ϭ 0.01) and the antiprogestins on activin-induced FSH release (P ϭ 0.02). In the presence of E 2 , the effect of the antiprogestins on FSH release was highly significant overall (P Ͻ 0.0001). In cells prepared from pituitaries collected on proestrous morning, the antiprogestins suppressed basal, but not activin-stimulated, FSH release even in the absence of added E 2 (P ϭ 0.0005). In the presence of E 2 added to the cultures, antiprogestins potently suppressed both basal and activin-stimulated FSH release (P Ͻ 0.0001).
the antiprogestins on FSH release with those of the natural agonist, P 4 , in cultured cells from metestrous rats (Fig. 3A) . In the absence of E 2 , 10 nm P 4 significantly increased FSH release; this increase was completely reversed by both antiprogestins. The small additional FSH response to P 4 above that induced by activin alone was similarly blocked by the antiprogestins. Addition of E 2 to the cell cultures increased the effects of P 4 on both basal and activin-stimulated FSH release and strongly enhanced the suppressive effects of the antiprogestins. P 4 did not have a significant effect on intracellular FSH content in the absence of E 2 , but increased this parameter significantly in E 2 -treated cells both under basal conditions and in combination with activin (Fig. 3B) .
Suppression of B-stimulated FSH secretion by the antiprogestins
Because previous work from our laboratory identified glucocorticoids as potent direct secretagogues for FSH (11, 16) , and because RU486 (17), but not ZK98299 (18), is an antiglucocorticoid as well as an antiprogestin, in Exp 4 we investigated whether the antiprogestins could suppress B-stimulated FSH secretion differentially or similarly. The effective concentration of B used in the previous studies ranged from 0.17-1.7 m; the concentration of the antiprogestins added to the culture medium was, therefore, increased to 1 m to match that of B used in the present study. As depicted in Fig. 4 , in E 2 -treated cells from metestrous rats, RU486 and ZK98299 induced similar suppression of both basal and B-stimulated secretion of FSH (P Ͻ 0.0001 overall); the magnitude of this suppression of FSH release by ZK98299 was slightly, but significantly (P ϭ 0.01), greater than that by RU486.
Differential responsiveness of FSH and LH to antiprogestins in vitro
The observed effects of the antiprogestins were highly specific for FSH. In no experiment could we demonstrate suppression of LH secretion by the antiprogestins; on the contrary, in several experiments in which LH was measured, ZK98299, but not RU486, significantly increased LH release in an E 2 -dependent manner. LH release measured in the same experiment for which FSH measurements are depicted in Fig. 1 , is shown in Table 1 . LH release, but not intracellular LH content, was selectively stimulated by ZK98299.
Discussion
This is the first report demonstrating that the effects of activin on FSH secretion can be antagonized by antiprogestins. Our data clearly indicate that both type I (ZK98299) and type II (RU486) antiprogestins are capable of causing profound suppression of FSH secretion only in gonadotropes that had been primed with E 2 . The present findings are consistent with our earlier demonstration of an E require- FIG. 3 . Effects of treatment with 10 nM progesterone (P 4 ) without or with 10 nM RU486 (RU) or ZK98299 (ZK) on basal and recombinant human activin (Act; 10 ng/ml)-stimulated FSH release during 48 -96 h (A) and intracellular FSH content at 96 h (B) in anterior pituitary cell cultures from metestrous rats exposed to vehicle or 10 nM E 2 throughout the 96-h incubation. Each bar is the mean, and the error bar the SEM of four observations. Addition of E 2 to the cell cultures increased the effects of P 4 on both basal and Act-stimulated FSH release and enhanced the suppressive effects of the antiprogestins (P ϭ 0.004 for the effect of E 2 overall). The effect of P 4 on intracellular FSH content was not significant in the absence of E 2 , but was highly significant (P Ͻ 0.0001) in cells incubated with E 2 under both basal conditions and in combination with Act. ment for RU486 to lower serum FSH in vivo and implicate E-inducible PR as mediators of this suppression. In E 2 -primed anterior pituitary cells, the antiprogestins induced profound, specific suppression of both basal and activin-or glucocorticoid-stimulated FSH secretion.
Previous work from our laboratory and others demonstrated that RU486 is capable of suppressing FSH secretion in in vitro systems after prior in vivo administration of the drug to the pituitary donor animals (19) or upon direct addition to primary anterior pituitary cell culture (20) . It is likely, however, that because of accumulation of locally produced activin (21) in the static cultures used in the latter study as well as in the present work, basal FSH secretion may, in fact, represent secretion stimulated by the autocrine or paracrine actions of endogenous activin (6) . Moreover, the effect of glucocorticoids may also be mediated by endogenous activin production; thus, all of the observed effects of the antiprogestins may have been on activin-stimulated FSH secretion.
The in vitro effects of the two antiprogestins on FSH secretion were qualitatively and quantitatively similar under virtually all experimental conditions; ZK98299 exhibited slightly, but significantly, greater biopotency than RU486 despite reports that the latter binds PR with 5-or 10-fold higher affinity (22, 23) . It is of interest to note that the only differential action of the two drugs observed in the present study was on LH release in E 2 -primed cells: only ZK98299, not RU486, increased LH release. Thus, the present results do not provide insight into the mechanism underlying the differential in vivo effects of the two antiprogestins on serum FSH on estrous morning. More recently, we performed an experiment (Szabo, M., S. M. Kilen, and N. B. Schwartz, unpublished) to investigate the possibility that the failure of ZK98299, administered on proestrus, to suppress serum FSH on the morning of estrus was due to its more rapid metabolic clearance than that of RU486. Administration of a second dose of ZK98299 6 h before blood collection resulted in suppression of serum FSH on estrous morning comparable to that induced by a single injection of RU486 on proestrus, lending support to the assumption that ZK98299 is, indeed, cleared more rapidly from the circulation.
Suppression of FSH secretion by the antiprogestins was demonstrated in the absence of the natural ligand for PR, P 4 , in the pituitary cell culture. It is reasonable to conclude, therefore, that ligand-independent activation of PR may interact with activin receptor-mediated signal transduction in activating the transcription of genes that are required for synthesis of the FSH␤ subunit and FSH biosynthesis and release. Such hypothetical, ligand-independent activation of PR-mediated processes by peptide hormone-mediated signaling is analogous to the GnRH self-priming phenomenon described by Turgeon and Waring (24) . These researchers demonstrated that a pulse of GnRH administered to pituitary cells cultured in the presence of E 2 , but in the absence of P 4 , potentiated the LH secretory response to subsequent pulses of GnRH or cAMP analog. Potentiation could be blocked by RU486, prompting the researchers to propose cross-communication between a GnRH receptor-activated protein kinase A pathway and PR. That ligand-independent activation of PR contributes to the primary and secondary surges of FSH was also suggested, but not proven conclusively, by our previous demonstration that RU486 is capable of attenuating the preovulatory and secondary FSH surges under conditions where circulating P 4 is virtually eradicated by aminoglutethimide administration (25) .
It is well established that RU486 can act as an agonist when cAMP-mediated signaling is activated (14, 26, 27) , and P 4 itself has been reported to have both stimulatory and inhibitory effects on FSH secretion (28) . Based on this evidence, we considered the possibility that the in vitro suppression of FSH secretion by the antiprogestins may have been due to agonist-like effects of the drugs. That this was not the case was clearly indicated by the finding that P 4 induced potent, concentration-dependent stimulation of FSH secretion, enhanced by priming with E 2 , in agreement with earlier reports by Drouin and Labrie (29) and Krey and co-workers (20) . Both antiprogestins added at a low concentration antagonized this action of P 4 independent of E 2 . Thus, the antiprogestins clearly affected FSH secretion through blockade of PR rather than through their activation.
In conclusion, we demonstrated E 2 -dependent suppression of activin-induced FSH secretion by RU486 and ZK98299 in primary anterior pituitary cell culture in vitro. The data suggest that E-inducible PR play a role as a regulator of FSH secretion through interaction with activin-mediated signal transduction pathways. 
